CA1190496A - Process for the preparation of human insulin or the derivatives thereof from pig insulin or the derivatives thereof - Google Patents
Process for the preparation of human insulin or the derivatives thereof from pig insulin or the derivatives thereofInfo
- Publication number
- CA1190496A CA1190496A CA000394297A CA394297A CA1190496A CA 1190496 A CA1190496 A CA 1190496A CA 000394297 A CA000394297 A CA 000394297A CA 394297 A CA394297 A CA 394297A CA 1190496 A CA1190496 A CA 1190496A
- Authority
- CA
- Canada
- Prior art keywords
- insulin
- human insulin
- obut
- pig
- thrb30
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 77
- 101000976075 Homo sapiens Insulin Proteins 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims abstract description 37
- 101000993800 Sus scrofa Insulin Proteins 0.000 title claims abstract description 36
- 230000008569 process Effects 0.000 title claims abstract description 35
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 239000012588 trypsin Substances 0.000 claims abstract description 17
- 102000004142 Trypsin Human genes 0.000 claims abstract description 14
- 108090000631 Trypsin Proteins 0.000 claims abstract description 14
- -1 threonine ester Chemical class 0.000 claims abstract description 12
- 102000004190 Enzymes Human genes 0.000 claims abstract description 9
- 108090000790 Enzymes Proteins 0.000 claims abstract description 9
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000004473 Threonine Substances 0.000 claims abstract description 9
- 230000001810 trypsinlike Effects 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 22
- 102000004877 Insulin Human genes 0.000 claims description 21
- 108090001061 Insulin Proteins 0.000 claims description 21
- 229940125396 insulin Drugs 0.000 claims description 18
- 125000006239 protecting group Chemical group 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 4
- 125000004185 ester group Chemical group 0.000 abstract description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229960002898 threonine Drugs 0.000 description 7
- 102000000496 Carboxypeptidases A Human genes 0.000 description 6
- 108010080937 Carboxypeptidases A Proteins 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000004026 insulin derivative Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 101100070104 Mus musculus Hacl1 gene Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 150000003587 threonine derivatives Chemical class 0.000 description 2
- 238000006257 total synthesis reaction Methods 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- BZCVUUOCIRSZBE-WGTBXUJISA-N (2S)-6-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-24,56-bis(2-carboxyethyl)-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-5-ylmethyl)-27,83-dimethyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39,77-tri(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(O)=O)NC1=O)C(C)C BZCVUUOCIRSZBE-WGTBXUJISA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- QOOWRKBDDXQRHC-BQBZGAKWSA-N L-lysyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN QOOWRKBDDXQRHC-BQBZGAKWSA-N 0.000 description 1
- 150000008551 L-threonines Chemical class 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 108700043016 des-Ala- insulin Proteins 0.000 description 1
- QTBSBXVTEAMEQO-DYCDLGHISA-N deuterio acetate Chemical compound [2H]OC(C)=O QTBSBXVTEAMEQO-DYCDLGHISA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 125000005805 dimethoxy phenyl group Chemical group 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- TVHCXXXXQNWQLP-DMTCNVIQSA-N methyl (2s,3r)-2-amino-3-hydroxybutanoate Chemical compound COC(=O)[C@@H](N)[C@@H](C)O TVHCXXXXQNWQLP-DMTCNVIQSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- GAPYKZAARZMMGP-UHFFFAOYSA-N pyridin-1-ium;acetate Chemical compound CC(O)=O.C1=CC=NC=C1 GAPYKZAARZMMGP-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19813101382 DE3101382A1 (de) | 1981-01-17 | 1981-01-17 | "verfahren zur herstellung von humanisulin oder dessen derivaten aus schweineinsulin oder dessen derivaten" |
| DEP3101382.1 | 1981-01-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1190496A true CA1190496A (en) | 1985-07-16 |
Family
ID=6122819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000394297A Expired CA1190496A (en) | 1981-01-17 | 1982-01-15 | Process for the preparation of human insulin or the derivatives thereof from pig insulin or the derivatives thereof |
Country Status (14)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK147437A (en) * | 1980-02-11 | 1900-01-01 | Process for preparing human insulin or threonine B30 esters of human insulin, or a salt or complex thereof | |
| EP0088117B1 (en) * | 1981-09-15 | 1986-09-24 | Nordisk Insulinlaboratorium | Process for preparing human insulin or b-30 esters thereof |
| EP0087238A1 (en) * | 1982-02-08 | 1983-08-31 | Biogen N.V. | Am improved method for preparing human insulin from non-human insulin |
| DE3209184A1 (de) * | 1982-03-13 | 1983-09-15 | Hoechst Ag, 6230 Frankfurt | Verfahren zur umwandlung von praeproinsulinanaloga zu insulinen |
| DK182483A (da) * | 1982-04-23 | 1983-10-24 | Wako Pure Chem Ind Ltd | Fremgangsmaade til semi-syntese af humant insulin og alkalisk protease til anvendelse derved |
| DE3333640A1 (de) * | 1983-09-17 | 1985-04-25 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung |
| DE3334407A1 (de) * | 1983-09-23 | 1985-04-04 | Hoechst Ag, 6230 Frankfurt | In position b 30 modifizierte insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus |
| PT93057B (pt) * | 1989-02-09 | 1995-12-29 | Lilly Co Eli | Processo para a preparacao de analogos da insulina |
| DE4028120C2 (de) * | 1990-09-05 | 1996-09-19 | Hoechst Ag | Verfahren zur Reinigung von Insulin und/oder Insulinderivaten |
| US5106510A (en) * | 1991-03-08 | 1992-04-21 | Enviroguard, Inc. | Combined filtration and fixation of heavy metals |
| DK0547544T3 (da) * | 1991-12-18 | 1997-09-08 | Hoechst Ag | Fremgangsmåde til fremstilling af insulinholdige opløsninger. |
| US5534488A (en) * | 1993-08-13 | 1996-07-09 | Eli Lilly And Company | Insulin formulation |
| DE4404168A1 (de) * | 1994-02-10 | 1995-08-17 | Hoechst Ag | Hirudinderivate und Verfahren zu deren Herstellung |
| RU2120299C1 (ru) * | 1995-06-08 | 1998-10-20 | Акционерное курганское общество "Синтез" | Способ получения высокоочищенного монокомпонентного инсулина |
| RU2126690C1 (ru) * | 1996-11-06 | 1999-02-27 | Анистратенко Николай Юрьевич | Способ очистки инсулина-сырца, получаемого из поджелудочной железы свиней |
| AU1111799A (en) | 1997-10-24 | 1999-05-17 | Eli Lilly And Company | Fatty acid-acylated insulin analogs |
| US6531448B1 (en) | 1997-12-23 | 2003-03-11 | Eli Lilly And Company | Insoluble compositions for controlling blood glucose |
| UA46666C2 (en) * | 2001-12-29 | 2006-01-16 | Omakooe Ltd Liability Company | Method for preparing dosage form of short-term acting insulin |
| UA46669C2 (uk) * | 2001-12-29 | 2005-12-15 | Товариство З Обмеженою Відповідальністю "Мако" | Спосіб приготування готової лікарської форми інсуліну пролонгованої дії |
| UA46667C2 (en) * | 2001-12-29 | 2006-01-16 | Omakooe Ltd Liability Company | Method for preparing semisynthetic human insulin |
| UA46668C2 (en) * | 2001-12-29 | 2006-01-16 | Omakooe Ltd Liability Company | Method for preparing combined dosage form of human insulin |
| US6964561B2 (en) * | 2002-04-23 | 2005-11-15 | V System Composites, Inc. | High-performance infusion system for VARTM fabrication |
| US20070108646A1 (en) * | 2005-11-15 | 2007-05-17 | Louderback Michael J | Method of fabricating a composite structure with details |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3276961A (en) * | 1963-04-08 | 1966-10-04 | Squibb & Sons Inc | Process for preparing human insulin |
| US3903068A (en) * | 1972-12-26 | 1975-09-02 | Us Health Education & Welfare | Facile synthesis of human insulin by modification of porcine insulin |
| DE2460753A1 (de) * | 1974-12-21 | 1976-06-24 | Hoechst Ag | Verfahren zur herstellung von humaninsulin |
| DK146482C (da) * | 1979-04-13 | 1986-10-06 | Shionogi & Co | Fremgangsmaade til fremstilling af et b30-threonin-insulin |
| DK147437A (en) * | 1980-02-11 | 1900-01-01 | Process for preparing human insulin or threonine B30 esters of human insulin, or a salt or complex thereof | |
| DK319780A (da) * | 1980-07-24 | 1982-01-25 | Forenede Bryggerier As | Fremgangsmaade til enzymatisk udskiftning af b-30 aminosyren i insuliner |
-
1981
- 1981-01-17 DE DE19813101382 patent/DE3101382A1/de not_active Withdrawn
-
1982
- 1982-01-12 ES ES508657A patent/ES8301206A1/es not_active Expired
- 1982-01-14 FI FI820117A patent/FI79860C/fi not_active IP Right Cessation
- 1982-01-14 JP JP57003544A patent/JPS57138396A/ja active Granted
- 1982-01-14 EP EP82100217A patent/EP0056951B1/de not_active Expired
- 1982-01-14 DE DE8282100217T patent/DE3264149D1/de not_active Expired
- 1982-01-14 AT AT82100217T patent/ATE13893T1/de active
- 1982-01-15 CA CA000394297A patent/CA1190496A/en not_active Expired
- 1982-01-15 GR GR67018A patent/GR74758B/el unknown
- 1982-01-15 ZA ZA82261A patent/ZA82261B/xx unknown
- 1982-01-15 IL IL64789A patent/IL64789A/xx active IP Right Grant
- 1982-01-15 DK DK16682A patent/DK149615B/da not_active Application Discontinuation
- 1982-01-15 AU AU79554/82A patent/AU559235B2/en not_active Expired
- 1982-01-18 KR KR8200188A patent/KR880001107B1/ko not_active Expired
-
1984
- 1984-08-15 US US06/641,357 patent/US4601852A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0056951B1 (de) | 1985-06-19 |
| FI79860C (fi) | 1990-03-12 |
| DK149615B (da) | 1986-08-11 |
| KR830008995A (ko) | 1983-12-16 |
| ZA82261B (en) | 1982-12-29 |
| ES508657A0 (es) | 1982-11-16 |
| AU559235B2 (en) | 1987-03-05 |
| IL64789A (en) | 1985-09-29 |
| DK16682A (da) | 1982-07-18 |
| AU7955482A (en) | 1982-07-29 |
| JPS57138396A (en) | 1982-08-26 |
| DE3101382A1 (de) | 1982-09-02 |
| GR74758B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1984-07-11 |
| JPH0141317B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1989-09-05 |
| ATE13893T1 (de) | 1985-07-15 |
| US4601852A (en) | 1986-07-22 |
| FI820117L (fi) | 1982-07-18 |
| FI79860B (fi) | 1989-11-30 |
| EP0056951A1 (de) | 1982-08-04 |
| KR880001107B1 (ko) | 1988-06-29 |
| DE3264149D1 (en) | 1985-07-25 |
| ES8301206A1 (es) | 1982-11-16 |
| IL64789A0 (en) | 1982-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1190496A (en) | Process for the preparation of human insulin or the derivatives thereof from pig insulin or the derivatives thereof | |
| US5015728A (en) | Process for the preparation of insulin derivatives, the B chain of which is lengthened c-terminally | |
| US6908897B2 (en) | Covalently bridged insulin dimers | |
| NO167810B (no) | Analogifremgangsmaate til fremstilling av insulinderivater. | |
| FI77876C (fi) | Foerfarande foer framstaellning av humaninsulin eller en treoninb30-ester av humaninsulin eller ett salt eller komplex daerav. | |
| CA2083360A1 (en) | Tri-arginine insulins | |
| US4489159A (en) | Process for preparing esters of human insulin | |
| CN114805525A (zh) | 一种芋螺肽的制备方法 | |
| FI79853B (fi) | Foerfarande foer framstaellning av insulinderivat. | |
| US4029642A (en) | Process for the manufacture of human insulin | |
| KR20090038868A (ko) | 이염기성 ｂ쇄 말단을 갖는 인슐린 유사체를 제조하는 방법 | |
| CA1195273A (en) | Process for converting preproinsulin analogs into insulin | |
| EP0088117B1 (en) | Process for preparing human insulin or b-30 esters thereof | |
| CA1045626A (en) | Process for the manufacture of peptides containing cystine | |
| CA1327868C (en) | Arginine derivative, process for the preparation thereof and its use in peptide synthesis | |
| EP0087238A1 (en) | Am improved method for preparing human insulin from non-human insulin | |
| US4212796A (en) | Process for the preparation of cysteine-containing peptides | |
| CA2057269A1 (en) | Process for the enzymatic preparation of grf(1-44)nh2 | |
| DE1941511C2 (de) | Calcitonin-Analoga und ihre α-Desamino- und N↑α↑-Acylaminoderivate, diese Peptide enthaltende pharmazeutische Präparate, und synthetische Verfahren zu ihrer Herstellung sowie zur Herstellung von Calcitonin M | |
| WEITZEL et al. | Structure and Activity of Insulin, XVl. Semisyntheses of Desheptapeptide-(B24—30)-up to Destripeptide-(B28—30)-Insulin with Lysine or Alanine in Place of Arginine in Position B22: Influence on the Three-Step-Increase of Activity in Positions B24—26 (Phe-Phe-Tyr) | |
| Bodanszky et al. | Partial Synthesis | |
| WO1984003107A1 (en) | A process for the preparation of human insulin | |
| NO163531B (no) | Beskyttet b30-thr(r1)(r2)-insulin egnet for fremstilling av et b30-threonininsulin. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |